Company Overview and News
KUALA LUMPUR (Oct 1): Kenanga Investment Bank Bhd (KIBB) has issued four new structured warrants covering the O&G sector, just as Brent crude oil prices surpassed US$80 a barrel this week.
0166 BRDBF 7022 5012 GBTKF 5210
Plantation sector Maintain neutral: Malaysia’s crude palm oil (CPO) production increased for a second straight month in August, rising by 7.9% month-on-month (m-o-m) to 1.62 million tonnes. The fresh fruit bunch (FFB) yield also improved across Peninsular Malaysia, Sabah and Sarawak, rising by 8.7%, 3.2% and 12.6% year-on-year (y-o-y) respectively to 1.38 tonnes/ha, 1.28 tonnes/ha and 1.52 tonnes/ha.
KLKBY 2445 5138 2216 4383 2291 4243 5012
KUALA LUMPUR (Sept 3): RHB Retail Research said Ta Ann Holdings Bhd may rebound further after it tested MYR2.56 support in recent trades.
KUALA LUMPUR: Plantation companies listed on the local bourse turned in weaker corporate earnings in the three months ended June 30, 2018, but analysts are positive about seeing improvements in the remaining months of the year.
Ta Ann Holdings Bhd (Aug 23, RM2.72) Maintain outperform call with an unchanged target price (TP) of RM3.19: Log prices have gradually climbed from US$276 per cubic metre (cu m) in second quarter of financial year 2017 (2QFY17) to US$368 (RM1,512.48) per cu m in 2QFY18, a whopping gain of 33% year-on-year (y-o-y).
CGSCIMB recently hosted Inari Amertron’s management on a roadshow in London. The research house said it had with 10 buy-side analysts and fund managers from eight investment firms. Inari Amerton was represented by group chief executive officer K.C. Lau and founder and executive director P.G. Ho.
KUALA LUMPUR (July 6): Based on corporate announcements and news flow today, stocks that may draw some attention on Monday (July 9) could be MISC, Red Sena, Top Glove, KUB Malaysia, Ta Ann, Protasco and Versatile Creative.
TGLVY 4995 5270 7113 TPGVF 6874 BSMAF 5012 1818
KUALA LUMPUR (July 6): Ta Ann Holdings Bhd has received its first ever sustainable forest management certification for its Malaysian operations, for its forest plantation in Sarawak.
PLANTERS will likely face tough sales and operational conditions following the drastic fall in crude palm oil (CPO) prices, which had been trading below RM2,300 per tonne level in recent weeks.
KLKBY 2445 WLMIY WLMIF SMEBF 4197 F34 5222 5012
BAD luck and ongoing timber woes are sapping the cash reserves of Ta Ann Holdings Bhd, which paid nearly RM171 million for 30.4% of Sarawak Plantation Bhd (SPLB) earlier this year.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...